Journal article
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses
Abstract
BACKGROUND: Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE with higher affinity than omalizumab.
OBJECTIVE: This study compared the effects of QGE031 with those of omalizumab on clinical efficacy, IgE levels, and FcεRI expression in a clinical model of allergic asthma.
Authors
Gauvreau GM; P. J; Boulet L-P; Leigh R; Cockcroft DW; Davis BE; Mayers I; FitzGerald JM; Dahlen B; Killian KJ
Journal
The Journal of Allergy and Clinical Immunology, Vol. 138, No. 4, pp. 1051–1059
Publisher
Elsevier
Publication Date
10 2016
DOI
10.1016/j.jaci.2016.02.027
ISSN
0091-6749